Skip to main content
Premium Trial:

Request an Annual Quote

Missed Early Cases

A new analysis suggests SARS-CoV-2 may have been present in parts of the US as early as late December 2019, the New York Times reports. It notes, though, that the study's small sample size may make it difficult to distinguish true and false positives.

 As they report in the journal Clinical Infectious Diseases, the researchers from the US National Institutes of Health's All of Us research project retrospectively tested more than 24,000 blood samples for SARS-CoV-2 antibodies. Of these samples, 147 had a positive result on one test and nine of those also had a positive result on a second antibody test. Seven of these nine samples were from before there were known COVID-19 cases in participants' states, and one collected in early January 2020 in Illinois that indicates the virus may have been present there in late December 2019, as it takes about two weeks for antibodies to develop.

This, the Times notes, is in line with previous analyses suggesting that early cases in the US and elsewhere may have been missed.

"It helps us understand a little bit more about the geographic spread of where the virus was in those very early days of the US epidemic," lead author Keri Althoff from the Johns Hopkins Bloomberg School of Public Health tells the Wall Street Journal.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.